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Prostate cancer is one of the most common neoplasms in men. Transrectal ultrasound (TRUS)-guided systematic biopsy has a crucial 
role in the diagnosis of prostate cancer. However, it shows limited value with gray-scale ultrasound alone because only a small number 
of malignancies are visible on TRUS. Recently, new emerging technologies in TRUS-guided prostate biopsy were introduced and 
showed high potential in the diagnosis of prostate cancer. High echogenicity of ultrasound contrast agent reflect the increased status 
of angiogenesis in tumor. Molecular imaging for targeting specific biomarker can be also used using ultrasound contrast agent for 
detecting angiogenesis or surface biomarker of prostate cancer. The combination of TRUS-guided prostate biopsy and ultrasound 
contrast agents can increase the accuracy of prostate cancer diagnosis. Elastography is an emerging ultrasound technique that can 
provide the information regarding tissue elasticity and stiffness. Tumors are usually stiffer than the surrounding soft tissue. In two 
types of elastography techniques, shearwave elastography has many potential in that it can provide quantitative information on 
tissue elasticity. Multiparametric magnetic resonance imaging (MRI) from high resolution morphologic and functional magnetic 
resonance (MR) technique enables to detect more prostate cancers. The combination of functional techniques including apparent 
diffusion coefficient map from diffusion weighted imaging, dynamic contrast enhanced MR and MR spectroscopy are helpful in the 
localization of the prostate cancer. MR-ultrasound (US) fusion image can enhance the advantages of both two modalities. With MR-US 
fusion image, targeted biopsy of suspicious areas on MRI is possible and fusion image guided biopsy can provide improved detection 
rate. In conclusion, with recent advances in multiparametric-MRI, and introduction of new US techniques such as contrast-enhanced 
US and elastography, TRUS-guided biopsy may evolve toward targeted biopsies rather than systematic biopsy for getting information 
reflecting the exact status of the prostate. 
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INTRODUCTION
Prostate cancer is the most common neoplasm in Europe 
and America occupying about 2 or 3 times more than lung 
and colorectal cancer [1,2]. The incidence is still rising as well 
as Asian countries including Japan and Korea. Screening, de-
tection and diagnosis of prostate cancer are currently based 
on serum prostate-specific antigen (PSA) levels, digital rectal 
examination and transrectal ultrasound (TRUS)-guided sys-
tematic biopsies [3]. 
 Only a small number of malignancies are visible on gray-
scale TRUS. On grayscale evaluation, prostate cancers are 
classically described as a hypoechoic lesion; however they 
may be isoechoic or hyperechoic (Fig. 1) [4,5]. The percent-
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simple procedure, it is still the most optimal technique for 
guiding prostate biopsies [3].
 Besides, recently, new emerging technologies in TRUS-
guided prostate biopsy were introduced and showed high 
potential in the diagnosis of prostate cancer. Ultrasound 
contrast agent studies can provide the information regard-
ing vascularity of the lesion. New novel technologies for the 
synthesis of new microbubbles (MBs) with specific ligand 
and visualize the portion with specific marker. The advent of 
ultrasonic molecular imaging may provide a new diagnostic 
method for the early diagnosis of prostate cancer. Elastogra-
phy is an emerging ultrasound technique that can provide 
the information regarding tissue elasticity and stiffness. The 
hybrid imaging, which can show the information both from 
multiparametric (MP) magnetic resonance imaging (MRI) 
and TRUS imaging, will have a potential modality in perform-
ing targeted biopsy. In this review article, the new upcoming 
technology which can be used in TRUS-guided biopsy will be 
introduced. 
DYNAMIC CONTRAST ENHANCED  
TRANSRECTAL PROSTATE ULTRASOUND
Sonographic contrast agents made up of MBs are composed 
of an outer shell and inner gas core, ranging in size from 1 to 7 
μm in diameter [12]. The thickness of outer shell is denatured 
albumin or phospholipids ranging from 10 to 200 nm [13]. 
The inner space is filled with gases having a high molecular 
weight and low solubility such as perfluorocarbon or sulfur 
hexafluoride which has characteristics of prolong the agents’ 
existence in the blood pool [14].  
 Ultrasound contrast agents are mainly used as intravascu-
lar contrast media although they can be instilled into urinary 
bladder to evaluate ureteric reflux or into the uterus to look 
ages of prostate cancers known from literature are around 
11%–35% [6]. The positive predictive value of the biopsy of a 
peripheral hypoechoic lesion is 25%–30% [4]. Furthermore, 
only in 17%–57% of the hypoechoic lesions seen on TRUS is 
malignancy present [7]. Many prostate cancers are not vis-
ible on conventional ultrasound, and any lesion visible on 
grayscale ultrasound has a high likelihood of having a benign 
cause. The differential diagnosis in evaluating the low echoic 
focal lesion includes inflammation, fibrosis, infarction or be-
nign prostate hyperplasia nodules.
 According to Onur et al. [8], prostate cancer was reported 
results of biopsy study of 3,912 consecutive patients revealed 
that prostate cancer was detected in 25.5% with a hypoechoic 
lesion, and in 25.4% without a hypoechoic lesion. The per-
centage of core detection was 9.3% for hypoechoic and 10.4% 
for iso-echoic areas. Over the past decade, there has been 
a trend to obtain larger numbers of biopsy specimens, with 
most clinicians taking 8- to 12-biopsy cores, most current 
studies are recommending a 12-core biopsy scheme [9]. Au-
topsy studies have demonstrated that sextant prostate biopsy 
sensitivities at 30%, with increasing sensitivity with increasing 
numbers of biopsy cores, 36%–58% for 12-core biopsies, and 
53%–58% for 18-core biopsies [10].
 In other attempts were tried. Lee et al. [11] tried to classify 
the focal lesions seen on TRUS with parameters of shape, 
margin irregularity, vascularity, the location of the lesion. 
They concluded that the positive predictive value was up 
to 80% when the focal lesion located in peripheral portion 
showed nodular, irregular, and increased vascularity. 
 In spite of these results, many research reports showed that 
the focal lesion shows low sensitivity and specificity of gray-
scale ultrasound for the detection of prostate cancer. And 
there is limited value for gray-scale-targeted biopsies. How-
ever, due to the high-quality images and the inexpensive and 
Fig. 1. Focal lesion seen on transrectal ultrasound (TRUS) and prostate magnetic resonance imaging in a 55-year-old man. (A) TRUS 
shows low echoic nodular lesion in left peripheral zone (arrow). TRUS guided biopsy for this lesion confirmed that the lesion was 
prostate cancer. (B) T2 weighted axial magnetic resonance scan shows relatively well defined nodular lesion in left peripheral zone 
(arrow). (C) Apparent diffusion coefficient map shows signal drop at the same lesion, which suggest diffusion restriction (arrow).
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detection rate of prostate cancer was higher when they use 
contrast enhanced color Doppler targeted biopsy comparing 
ten systemic biopsies in 690 men (26% vs. 20%). The Gleason 
score was also higher in contrast enhanced color Doppler 
targeted biopsy than that of systemic biopsy (mean: 6.8 vs. 
5.4). In recent report published by Jiang, the peak intensity on 
contrast enhanced ultrasound correlated with Gleason score 
and MVD in 147 prostate cancer patients [21]. 
 Li et al. [22] reported meta-analysis reports regarding the 
diagnostic performance of contrast enhanced ultrasound 
in patients with prostate cancer. The pooled sensitivity and 
specificity were 0.7 and 0.74 from 2,624 patients who were 
included in their meta-analysis. They concluded that contrast 
enhanced ultrasound is a promising tool in the detection of 
prostate cancer, but it cannot completely replace systematic 
biopsy under the present circumstances. 
TARGETED ULTRASOUND CONTRAST 
AGENT SPECIFIC TO PROSTATE CANCER 
Targeted MBs are new generation of ultrasound contrast 
agent. These bubbles have additional ligand molecules that 
bind to the specific sites. Possible receptor targets for prostate 
cancer are those that are up-regulated during the process 
of angiogenesis. Most research has been focusing on the 
vascular endothelial growth factor (VEGF) receptors [23]. Ex-
ploiting the high expression of VEGF receptor 2 (VEGFR2) in 
tumor neovasculature, Fischer et al. [24] developed VEGFR2 
receptor-loaded targeted micrometer-scale MBs based on the 
conventional MB and compared the contrast enhancement 
of conventional MB and VEGFR2 receptor-loaded MB in 
prostate cancer and normal prostate tissue. 
 There are other novel technologies for targeting prostate 
cancer cells using nanoscale ultrasound contrast agents. As 
well-known tissue marker of prostate cancer, prostate-specific 
membrane antigen (PSMA) is considered to be the most im-
portant protein target in diagnostic specific immunolocaliza-
tion imaging and immune-directed therapy [25,26]. Current 
studies have demonstrated that PSMA is a type II transmem-
brane glycoprotein in the prostate cell membrane. The levels 
of PSMA expression are different in normal prostate tissue, 
benign prostatic hyperplasia and prostate cancer epithelial 
tissue. And it is also known that PSMA positive expression 
rate in hormone refractory prostate cancer and metastases 
are significantly higher than that of the normal or benign tis-
sue [25].
 Loading nanoscale MBs with prostate cancer-targeted 
specific ligands or antibodies is critical for specific ultrasound 
out tubal patency [15,16]. The size of MB is equal to that of 
red blood cells and they behave as intravascular blood pool 
agents (Fig. 2).
 The tumor growth and metastasis require angiogenesis, the 
growth of new blood vessels. The measure of tumor angio-
genesis correlates with the microvessel density (MVD) and 
metastasis in various malignancies [17]. Hence, MBs have 
considerable potential for imaging of tumor angiogenesis in 
preclinical studies using small animal models. According to 
our preclinical study in xenograft prostate cancer model using 
PC-3 prostate tumor cells, maximum intensity was positively 
correlated with the MVD with statistical significance [18]. 
Weidner et al. [17] reported that microvessel counts increased 
with increasing Gleason score in prostatectomy specimen. 
In 2001, Sedelaar et al. [19] showed that ultrasound contrast 
enhanced areas had a 1.93 times higher MVD as compared to 
the nonenhanced areas.  
 In clinical practice, contrast enhanced sonography has 
many advantages in that it can be performed on patients 
safely, easily, and repeatedly without any radiation. However, 
contrast enhanced sonography has disadvantages in its lack of 
objectivity in determining the extent of enhancement because 
the image qualities are affected by many factors, and they 
are sometimes operator dependent. Even though the several 
software for semiquantitative analysis about dynamic contrast 
study were developed and embedded in ultrasound machine, 
the disadvantages of lack of objectiveness still exists.
 Many clinical researches were performed for the evalu-
ation of the TRUS-guided biopsy results using ultrasound 
contrast agents. According to Mitterberger et al. [20], the 
Fig. 2. Contrast enhanced transrectal ultrasound (TRUS) find-
ings of prostate cancer in a 62-year-old man. Contrast en-
hanced TRUS image shows increase vascularity and contrast 
agent signals from left peripheral zone suggesting increased 
vascularity (arrows). Note that the focal lesion shows low echo-
genicity in gray-scale TRUS, which is one of common findings 
of prostate cancer. This lesion was confirmed as prostate cancer 
after TRUS guided targeted biopsy.
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imaging in prostate cancer. Wang et al. [26] reported in vi-
tro and in vivo results of PSMA-targeted nanoscale MBs in 
prostate cancer. They synthesized stable PSMA monoclonal 
antibody-loaded MBs using biotin-avidin complex technol-
ogy and investigate their in vitro target binding capability 
with the selected prostate cancer cells. In addition, targeted 
contrast enhancement and specificity were also examined 
with a xenograft prostate tumor models. The results showed 
that targeted nanoscale MBs can significantly increase peak 
intensity and duration of contrast enhancement than blank 
nanoscale MBs in transplanted prostate tumors. Increased 
peak intensity and prolonged duration of enhanced contrast 
are the main characteristics of targeted nanoscale MB en-
hanced imaging [26].
 Even though these targeted ultrasound contrast agents are 
on the stage of clinical trial and preclinical study, it would be 
very potential methodology for targeted ultrasound guided 
prostate biopsy. 
ELASTOGRAPHY
Elastography is an emerging ultrasound technique that can 
visualize tissue elasticity and stiffness [27]. It is based on the 
assumptions that if force is applied to the unit area (stress), 
relative displacement of points (strain) will be proportional 
to the applied force and is represented by well-described 
Young’s modulus. Tumors are usually stiffer than normal tis-
sue because of its increased cellular density. Prostatic cancer 
is normally 5–28 times stiffer than the surrounding soft tissue 
[28]. This change of local stiffness is the background of digital 
rectal exam of prostate gland. However, digital rectal exam 
is subjective to the examiner and only part of prostate is pal-
pable. 
 There are two types of elastography; using strain and shear 
wave. Strain forces are generated by manual compression by 
transducers, while shear wave is a technique that uses a so-
nographic push pulse to generate a shear wave in the tissues 
[29]. A strain profile in a direction perpendicular to the tissue 
surface in response to an externally applied force is calcu-
lated in compression elastography. Tissue deformation is es-
timated from the relative difference in tissue movement from 
one to another frame. The deformation measurements are 
mapped on elastogram, stiffer areas as dark and more-elastic 
area as brighter color (Fig. 3). Elastography permits depiction 
of the cancer of isoechogenecity on gray scale ultrasound 
(US), otherwise can be missed by conventional TRUS.
 A metaanalysis study of US elastography using strain re-
ported sensitivity in the range of 71%–82%, a specificity of 
60%–95% with reference standard of radical prostatectomy 
specimen [30]. Elastography guided prostate biopsies in 
patients with cancer were 2.9 folds more likely to detect pros-
tate cancer than systemic biopsy, while requiring fewer core 
samples [31].
 Another prospective study of elastography by Brock et al. 
[32] concluded that overall prostate cancer detection rate was 
significantly higher in patients who underwent biopsy with 
Fig. 3. Typical prostate cancer seen on transrectal ultrasound (TRUS) and elastography in a 60-year-old man. (A) Gray-scale TRUS 
shows low echoic focal lesion in right lobe of prostate gland (arrow). (B) Elastography shows bluish color on right lobe, suggesting 
more rigidity comparing surrounding prostate tissue. Stiffness ratio of this focal lesion to contralateral normal area was 3.5, which 
means that 3.5 times stiffer than contralateral area by measurement of circular region of interest.
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the elastography guided approach compared to the gray scale 
ultrasound guided biopsy (51.1% vs. 39.4%). However the 
sensitivity of elastography did not reach levels to omit a sys-
tematic biopsy approach.
 Even comparison of elastography with T2 weighted con-
ventional MRI was reported by Aigner et al. [33]. Overall sen-
sitivities and specificities were similar between elastography 
and T2 weighted MRI. Negative predictive values of both 
studies are over 80%, these findings are both examinations 
may be useful to obviate the need for prostate biopsy.
 The drawback of strain elastography is that quantification 
of tissue elasticity is not achievable. Semiquantitative stiff-
ness evaluation using a strain index (strain ratio of tissue over 
normal tissue) is introduced to overcome this limitation and 
reported to be useful in the evaluation of prostate cancer [34]. 
At the cutoff value of 17.44, elastography yielded sensitivity 
of 74.5% and specificity of 83.3% for discriminating prostate 
cancer from benign lesions. However, these studies are all 
based on region of interest drawing, which have some diffi-
culties in reproducibility and standardization.
 Shear wave elastography (SWE) is another type of elastog-
raphy that can provide quantitative information on tissue 
elasticity. Another advantage of SWE over strain elastography 
is that SWE does not require compression by the transducer, 
which means that measurement is operator independent. 
A few initial reports showed very promising results for SWE, 
including high sensitivities and specificities over 90% for 
prostate cancer [29,35]. However, the sensitivity and specific-
ity were decreased to be 50% to 60% in another recent study 
by Woo et al. [36]. Nevertheless, SWE parameters of mean 
stiffness and mean stiffness ratio are significantly different 
between prostate cancer and benign tissue and correlate with 
Gleason score.
 Therefore, more validation studies beyond the initial hype 
will be required for the clinical implication of SWE through 
more objective measurement of SWE parameters, prospec-
tive trials and radical prostatectomy specimen basis. 
MR-US FUSION PROSTATE BIOPSY
TRUS plays a crucial role in the screening imaging study 
and guidance of the biopsy of the prostate glands. However, 
overall detection rate of TRUS for prostate cancer remains 
approximately 50%, and biopsies yield at least 1 positive bi-
opsy in only 25% of the patients [37,38]. Increasing number 
of biopsy cores is reported to improve cancer detection rates 
[39]. However, outnumbered core biopsy jeopardizes patients 
by increased complication rates. Moreover, over detection of 
the clinically insignificant cancer is another important issue, 
which leads to overtreatment. Nearly 50% of currently detect-
ed prostate cancer cases may be insignificant [40]. Therefore, 
detection of highest grade or representative cancer tissue in 
the prostate gland is required to decide optimal treatment 
plan.
 Application of stronger magnet and MP MRI from mor-
phologic and functional MRI technique enables to detect 
more cancers. T2 weighted MRI is excellent in the evaluation 
of anatomy and detection of peripherally located cancer. 
However, T2 weighted image has limited value in the detec-
tion of central gland cancer. In addition, T2 weighted images 
are very susceptible to post biopsy change, which shows low 
signal intensity and hampers tumor detection [41].
 Introduction of 3.0 Tesla MRI in clinical field impacts im-
proved image quality from increased signal to noise ratio. Still 
there remain some controversies, but the use of fearsome 
endorectal coil is not obligatory for the prostate MRI because 
of its increased signal to noise ratio of 3.0 Tesla MRI [42].
 Functional techniques including apparent diffusion coef-
ficient (ADC) map from diffusion weighted imaging, dynamic 
contrast enhanced MRI with fast imaging and magnetic reso-
nance (MR) spectroscopy are very helpful in the diagnosis 
of prostate cancer. The detection rates of prostate cancer are 
increased with these techniques, and even centrally located 
cancer can be more easily and confidently diagnosed [43]. 
For the staging of prostate cancer, MP MRI is superior to de-
tect extracapsular extension and seminal vesicle invasion. To 
monitor treatment effect, MP MRI significantly improves the 
assessment of patients with suspected recurrence after treat-
ment [44].
 ADC map can discriminate cancers with Gleason score 
over 7 (4+3) from cancer with lower Gleason score [43]. Be-
cause of this superior detectability of cancer with highest 
Gleason score with MRI, MRI guided prostate biopsy is intro-
duced. Although, it has great advantage of reducing the num-
ber of biopsy core, the increased procedure time and costs 
make the approach impractical [45].   
 MR-US fusion image can be another powerful option for 
guidance of prostate biopsy (Fig. 4). Reduction of time and 
cost of direct MRI guidance without sacrificing diagnostic 
accuracy can be achievable. Sonn et al. [45] reported that 
targeted biopsy with MR-US fusion was 3 times more likely to 
identify cancer than a systematic biopsy (27% vs. 7%). Of the 
men with Gleason score 7 or greater cancer 38% had disease 
detected only on targeted biopsies. Fusion biopsy can pro-
vide improved detection of prostate cancer in men with prior 
negative biopsies and elevated PSA values [46] .
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 There is still some technical issue to be solved in MR-US 
fusion. Precise registration of MR and US is the key for the 
successful image fusion. MRI can be performed with either 
pelvic array surface coil or endorectal coil. The prostate gland 
inevitably deformed during TRUS by introducing ultrasound 
transducer. Nonrigid registration of the prostate gland for 
this elastic deformation is needed, but still many fusion tech-
niques are based on rigid registration which cannot reflect 
elastic deformation by transducer. However, this issue can be 
overcome by development of fusion technique [47].
CONCLUSIONS 
Gray-scale TRUS is the gold standard for prostate imaging 
and is essential tool for TRUS guided prostate biopsy. With 
current trends in demanding more tissue and more cores 
to constitute a satisfactory sampling of the prostate, many 
solutions to increase sensitivity and to decrease the number 
of cores are suggested. MBs, which have inner gas and outer 
biocompatible shells composed of phospholipids or dena-
tured albumin, are good ultrasound contrast agents for the 
visualization of the vascular morphology and perfusion in the 
malignant lesions. Using MBs, microvascular abnormalities 
related to tumor angiogenesis in prostate cancer can be iden-
tified and represent an ideal biopsy target representing whole 
status of prostate. 
 Elastography reflects the tissue elasticity and stiffness in 
prostate. Although not yet established for routine clinical use, 
US elastography is a promising adjunctive modality for evalu-
ating prostate lesions. Between two types of elastography, 
shearwave elastography has several advantages in that it can 
provide quantitative information on tissue elasticity and does 
not need manual compression. Therefore, more validation 
studies will be needed for the evaluation about the role of 
elastography in the diagnosis of prostate cancer. 
 MP MRI, which includes T2 weighted image, diffusion 
weighted image, and dynamic contrast enhanced image, 
gives us information regarding prostate cancer. The MRI im-
ages can be used to guide TRUS-guided biopsy via image 
registration and fusion. With MR-US image fusion, targeted 
biopsy of suspicious areas on MRI is possible. 
 In conclusion, with recent advances in MP MRI, and intro-
duction of new US techniques such as contrast-enhanced US 
and elastography, TRUS-guided biopsy may evolve toward 
targeted biopsies rather than systematic biopsy for getting 
information about exact status of the prostate. 
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